HK1045541A1 - 用於高脂血的測試治療或預防的方法 - Google Patents

用於高脂血的測試治療或預防的方法

Info

Publication number
HK1045541A1
HK1045541A1 HK02106979.0A HK02106979A HK1045541A1 HK 1045541 A1 HK1045541 A1 HK 1045541A1 HK 02106979 A HK02106979 A HK 02106979A HK 1045541 A1 HK1045541 A1 HK 1045541A1
Authority
HK
Hong Kong
Prior art keywords
hyperlipemia
remedy
preventive
testing
testing remedy
Prior art date
Application number
HK02106979.0A
Other languages
English (en)
Chinese (zh)
Inventor
Koishi Ryuta
Ono Mitsuru
Furukawa Hidehiko
Horikoshi Hiroyoshi
Fujiwara Toshihiko
Ando Yosuke
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HK1045541A1 publication Critical patent/HK1045541A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02106979.0A 1999-12-09 2002-09-25 用於高脂血的測試治療或預防的方法 HK1045541A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34997699 1999-12-09
PCT/JP2000/008722 WO2001042499A1 (fr) 1999-12-09 2000-12-08 Procede d'essai d'agent curatif ou preventif de l'hyperlipemie

Publications (1)

Publication Number Publication Date
HK1045541A1 true HK1045541A1 (zh) 2002-11-29

Family

ID=18407394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106979.0A HK1045541A1 (zh) 1999-12-09 2002-09-25 用於高脂血的測試治療或預防的方法

Country Status (17)

Country Link
US (3) US20030017488A1 (ko)
EP (1) EP1239050A4 (ko)
KR (1) KR20020062652A (ko)
CN (1) CN1433482A (ko)
AU (1) AU768034B2 (ko)
BR (1) BR0016257A (ko)
CA (1) CA2390676A1 (ko)
CZ (1) CZ20021853A3 (ko)
HK (1) HK1045541A1 (ko)
HU (1) HUP0203408A3 (ko)
IL (1) IL149849A0 (ko)
MX (1) MXPA02005758A (ko)
NO (1) NO20022711L (ko)
PL (1) PL355666A1 (ko)
RU (1) RU2002115295A (ko)
WO (1) WO2001042499A1 (ko)
ZA (1) ZA200204432B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039986A1 (en) * 2000-11-03 2003-02-27 Yongming Sun Compositions and methods relating to prostate specific genes and proteins
IL159153A0 (en) * 2001-06-08 2004-06-01 Sankyo Co Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
JPWO2003028445A1 (ja) * 2001-08-31 2005-01-13 大塚製薬株式会社 Ｔｓａ２３０６遺伝子欠損非ヒト動物
DK2121751T3 (en) 2006-12-08 2017-04-24 Lexicon Pharmaceuticals Inc Monoclonal antibodies to ANGPTL3
US8143600B2 (en) * 2008-02-18 2012-03-27 Visiongate, Inc. 3D imaging of live cells with ultraviolet radiation
DK2521556T3 (en) * 2010-01-08 2018-08-13 Ionis Pharmaceuticals Inc MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
RU2019110030A (ru) 2013-05-01 2019-05-06 Ионис Фармасьютикалз, Инк. Композиции и способы
PL3087183T3 (pl) 2013-12-24 2021-01-11 Ionis Pharmaceuticals, Inc. Modulacja ekspresji białka angiopoetynopodobnego 3
BR112016024850B1 (pt) 2014-05-01 2021-07-06 Ionis Pharmaceuticals, Inc compostos e composições para modulação da expressão de angptl3 e seus usos
KR20180073606A (ko) 2015-11-06 2018-07-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
US10995335B2 (en) 2017-09-14 2021-05-04 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
CN109806632A (zh) * 2019-03-01 2019-05-28 中国科学院武汉物理与数学研究所 一种全血过滤装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005972A1 (en) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
CA2332109A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1161536A1 (en) * 1998-11-17 2001-12-12 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
AU771751C (en) * 1998-12-01 2006-04-06 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ATE432987T1 (de) * 1998-12-22 2009-06-15 Genentech Inc Verfahren und zusammensetzungen zur hemmung des neoplastischen zellenwachstums
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
JP2000325087A (ja) * 1999-05-21 2000-11-28 Otsuka Pharmaceut Co Ltd Ｔｓａ２３０６遺伝子
EP1210363A2 (en) * 1999-07-16 2002-06-05 Hyseq, Inc. Novel angiopoietin materials and methods

Also Published As

Publication number Publication date
PL355666A1 (en) 2004-05-04
NO20022711D0 (no) 2002-06-07
NO20022711L (no) 2002-08-08
ZA200204432B (en) 2003-09-29
MXPA02005758A (es) 2002-09-18
HUP0203408A3 (en) 2005-01-28
AU768034B2 (en) 2003-11-27
EP1239050A1 (en) 2002-09-11
CA2390676A1 (en) 2001-06-14
US20030211533A1 (en) 2003-11-13
RU2002115295A (ru) 2004-01-10
IL149849A0 (en) 2002-11-10
KR20020062652A (ko) 2002-07-26
EP1239050A4 (en) 2004-07-21
AU1887001A (en) 2001-06-18
WO2001042499A1 (fr) 2001-06-14
US20030017488A1 (en) 2003-01-23
BR0016257A (pt) 2002-08-20
CN1433482A (zh) 2003-07-30
US20030207251A1 (en) 2003-11-06
HUP0203408A2 (hu) 2003-01-28
CZ20021853A3 (cs) 2002-11-13

Similar Documents

Publication Publication Date Title
EP1181293A4 (en) CUCURBITURILS AND METHODS OF SYNTHESIS
SG86377A1 (en) Method of sterilization
HUP0203408A3 (en) Method of testing remedy or preventive for hyperlipemia
EP1076874A4 (en) METHOD AND CIRCUIT FOR COMPENSATING THE NON-LINEARITY OF CAPACITORS
IL146769A0 (en) Method of sterilizing
IL142938A0 (en) Microbiological method for the preparation of an epothilone
EP1065494A4 (en) METHOD FOR TESTING THE HARDNESS OF A MICRO-REGION
EP1105725A4 (en) MATERIAL PROPERTY TEST SYSTEM
HUP0102924A3 (en) Method for testing enclosure of containers
PL339832A1 (en) Method of obtaining aromatic compounds
SG90756A1 (en) Method of reading mark and apparatus for the same
SG93276A1 (en) Method for the testing of electronic components
PL341752A1 (en) Method of obtaining aryloamino hydroxyantraquinones
TW420303U (en) Test equipment for determining open or short circuit of pico-fuse
PL339287A1 (en) Method of obtaining heterocyclic compounds and novel intermediate compounds
PL340733A1 (en) Method of obtaining derivatives of 2-aminothiazocarboxamide
GB2354069B (en) Testing method
EP1212626A4 (en) METHOD FOR TESTING CIRCUITS
GB9801496D0 (en) Method of testing
PL332676A1 (en) Method of obtaining benzidamine hydrochloride
PL333334A1 (en) Method of obtaining silylethenes
GB9925581D0 (en) Method of RAMDAC testing
HU9900219V0 (en) General equipment for determining of toxicity
PL329342A1 (en) Method of testing painting for their authenticity
GB9906326D0 (en) Inspection of matter